{"id":"W4391884527","doi":"10.1158/2767-9764.crc-22-0516","title":"CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma","year":2024,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Chugai Pharmaceutical; Stand Up To Cancer; Genentech; Ipsen; Servier; Eisai; Incyte; Astex Pharmaceuticals; Novocure; Sanofi; Exelixis; BioClinica; Regeneron Pharmaceuticals; National Institutes of Health; Helsinn; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Hepatitis C virus; Internal medicine; Hepatitis C; Titer; Gastroenterology; Hepacivirus; Discontinuation; Immunology; Oncology; Virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006662207,0.0002073796,0.0003961673,0.0006565191,0.000200454,0.00006725545,0.0003271693,0.0000980742,0.0001053695],"category_scores_gemma":[0.0001912254,0.0001510937,0.0000584767,0.001724327,0.0007900429,0.0002703762,0.0002178417,0.001238234,0.00001975342],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001176175,"about_ca_system_score_gemma":0.00128187,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02696107,"about_ca_topic_score_gemma":0.009237926,"domain_scores_codex":[0.9972709,0.000440337,0.0003287237,0.0004272071,0.0009957869,0.0005370281],"domain_scores_gemma":[0.9970016,0.0003048457,0.00005649442,0.001511091,0.0008553565,0.0002705848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009045774,0.0003239641,0.9784538,0.0002677681,0.0001215331,0.00001576033,0.0004876255,0.00005725193,0.0008473446,0.0002656307,0.000150382,0.01810433],"study_design_scores_gemma":[0.002481906,0.003055809,0.9840279,0.001904308,0.00002845461,0.000003154674,0.00002552151,0.005743188,0.0009664074,0.00005039583,0.0015492,0.0001637227],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925487,0.002748449,0.00003928,0.0008065212,0.00001769287,0.00182904,0.0001176403,0.00005103133,0.001841661],"genre_scores_gemma":[0.9892971,0.009074286,0.0004939745,0.00002060969,0.00002184309,0.0007364784,0.0001057822,0.00006627219,0.0001836709],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01794061,"threshold_uncertainty_score":0.9795185,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07582060412169538,"score_gpt":0.4308331225200983,"score_spread":0.3550125183984029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}